New obesity drug tested in chinese teens
NCT ID NCT06536023
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This early-stage trial tested the safety and tolerability of a new drug called IBI362 in 36 Chinese adolescents aged 12 to 17 with obesity. Participants had not lost significant weight through diet and exercise alone. The study compared those who received the drug to those who received a placebo, focusing on side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Children's Hospital, Capital Medical University Affiliated
Beijin, Beijin, 100045, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.